Khalid AL. Naamani: Efficacy, Safety, and Patient Selection of DOACs in Cirrhosis
Khalid AL. Naamani, Executive Committee Member Ministry of Health Oman, Chairman of The Medical City for Military and Security Services, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
”I’m pleased to share our recent publication: Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis: From Pharmacology to Clinical Practice
In this review, we explore the evolving role of direct oral anticoagulants (DOACs) in the management of portal vein thrombosis (PVT) in patients with cirrhosis.
Key highlights:
- Hemostasis in cirrhosis is a complex, rebalanced state rather than a simple bleeding tendency
- DOACs offer a promising alternative to traditional anticoagulants, with convenient fixed dosing and favorable safety profiles
- Evidence suggests comparable – and in some cases superior – recanalization rates versus VKAs, without a significant increase in major or variceal bleeding
- Careful patient selection remains essential, particularly based on liver function (CTP classification), renal status, and transplant candidacy
While current data are encouraging, further prospective studies are still needed, especially in patients with more advanced cirrhosis.
Grateful to my co-authors and collaborators for their valuable contributions to this work.”
Title: Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis: From Pharmacology to Clinical Practice
Authors: Khalid M. Al Naamani, Sundus Rizwan, Siham Al Sinani, Bader Al Rawahi, Sheikha AlMa’mari, Mohamed El-Kassas
Read the Full Article on Clinical and Applied Thrombosis/Hemostasis
Stay updated on all scientific advances with Hemostasis Today.
-
May 29, 2026, 13:49Tareq Abadl: The Rh Blood Group System – Meet the 5 Antigens That Matter Most
-
May 29, 2026, 13:39Kalyan Roy: Hematopoietic Stem Cell Transplantation in Thalassaemia
-
May 29, 2026, 12:53Wolfgang Miesbach: The Risk of Deskilling in Modern AI Assisted Medicine
-
May 29, 2026, 12:20Pall T. Onundarson: Is Anonymous Peer Review Always Objective
-
May 29, 2026, 11:59Jolene Ng: New Review Explores the Pathophysiology of Pre-Eclampsia
-
May 29, 2026, 11:44Lynne Baird: Why Expanding Bleed Control Kits Across Public Transport Matters
-
May 29, 2026, 11:30Rumbidzai Mushambi: When ‘Just Hormones’ Delays Real Diagnosis
-
May 29, 2026, 09:53Yassin Taher: Recognizing Clonal Eosinophilic Disorders in Pediatric Hypereosinophilic Syndrome
-
May 29, 2026, 09:52Sergio Emanuel Kaiser: Ruvonoflast and a New Anti-Inflammatory Strategy for Residual Cardiovascular Risk